SAN DIEGO—The Accelerating Medicines Partnership (AMP) is a public-private collaboration involving the National Institutes of Health (NIH), the U.S. Food & Drug Administration (FDA), multiple biopharmaceutical and life science companies, and nonprofit organizations, all joined together with the goal of transforming diagnosis and treatments for a multitude of diseases. One such condition that has been…
Accelerating Medicines Partnership Shares Its Progress on RA/Lupus Network
CHICAGO—“Why do so many drugs fail in clinical trials?” asked Michael Brenner, MD, chief of rheumatology, immunology and allergy at Brigham and Women’s Hospital in Boston. This question, previously posed by Francis Collins, MD, PhD, director of the National Institutes of Health, prompted a discussion among scientists and stakeholders in the pharmaceutical industry. The conversation…
AMP RA/Lupus Network Shares Its Progress
Researchers from the AMP RA/Lupus Network came together in June at the annual FOCIS meeting to share their progress as they perform a systematic molecular deconstruction of human diseases…
Accelerating Medicines Partnership Advances Research for Autoimmune Diseases
Advancing the understanding of autoimmune diseases has implications for precision medicine, according to Robert Carter, MD, of the NIH. Research funded through the NIH’s Accelerating Medicines Partnership has the potential to develop better biomarkers and clinical trials for lupus and RA, paving the way for more personalized treatment…